Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PORCN | Q9H237 | 2/20 | 1.00 |
| ▸ | WNT3A | P56704 | 15/20 | 0.81 |
| ▸ | PSEN1 | P49768 | 2/20 | 0.67 |
| ▸ | PSEN2 | P49810 | 2/20 | 0.67 |
| ▸ | APH1B | Q8WW43 | 2/20 | 0.67 |
| ▸ | NCSTN | Q92542 | 2/20 | 0.67 |
| ▸ | APH1A | Q96BI3 | 2/20 | 0.67 |
| ▸ | PSENEN | Q9NZ42 | 2/20 | 0.67 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29351470 | 1.00 | PORCN (1.00) | PORCNWNT3APSEN1PSEN2APH1B | |
| SCHEMBL1723593 | 0.90 | WNT3A (1.00) | PORCNWNT3APSEN1PSEN2APH1B | |
| SCHEMBL2182327 | 0.90 | WNT3A (1.00) | PORCNWNT3APSEN1PSEN2APH1B | |
| SCHEMBL1723832 | 0.89 | WNT3A (1.00) | PORCNWNT3A | |
| SCHEMBL2454059 | 0.86 | WNT3A (1.00) | PORCNWNT3APSEN1PSEN2APH1B | |
| SCHEMBL27971532 | 0.86 | WNT3A (0.93) | PORCNWNT3APSEN1PSEN2APH1B | |
| SCHEMBL2182842 | 0.86 | WNT3A (0.93) | PORCNWNT3APSEN1PSEN2APH1B | |
| SCHEMBL2184335 | 0.84 | WNT3A (0.80) | PORCNWNT3APSEN1PSEN2APH1B | |
| SCHEMBL2184404 | 0.84 | WNT3A (0.80) | PORCNWNT3APSEN1PSEN2APH1B | |
| SCHEMBL1492885 | 0.83 | PORCN (0.71) | PORCNWNT3APSEN1PSEN2APH1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 138 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250064859-A1 | HPSC-DERIVED ARTICULAR CHONDROCYTE COMPOSITIONS, SYSTEMS AND METHODS OF USE THEREOF | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2025-02-27 | — | — | US | claimed |
| EP-4493679-A1 | HPSC-DERIVED ARTICULAR CHONDROCYTE COMPOSITIONS, SYSTEMS AND METHODS OF USE THEREOF | The Children's Medical Center Corporation (US) | 2025-01-22 | — | — | EP | claimed |
| CN-118355110-A | Method for producing cartilage and bone | 默多克儿童研究所 | 2024-07-16 | — | — | CN | claimed |
| WO-2024052931-A1 | A PROTOCOL FOR GENERATING NEURAL PROGENITOR CELLS AND IMPLEMENTATIONS THEREOF | EYESTEM RESEARCH PRIVATE LIMITED (IN) | 2024-03-14 | — | — | WO | claimed |
| WO-2023178239-A1 | HPSC-DERIVED ARTICULAR CHONDROCYTE COMPOSITIONS, SYSTEMS AND METHODS OF USE THEREOF | THE CHILDREN'S MEDICAL CENTER CORPORATION (US) | 2023-09-21 | — | — | WO | claimed |
| US-20200224159-A1 | UNIFIED CELL DIFFERENTIATION PROTOCOL | EYESTEM RESEARCH PRIVATE LIMITED (IN) | 2020-07-16 | — | — | US | claimed |
| WO-2020068665-A1 | USE OF COLLAGEN BINDING DOMAINS TO DELIVER PRODUCTS TO SKIN | FABIUS BIOTECHNOLOGY (US) | 2020-04-02 | — | — | WO | claimed |
| US-20160303137-A1 | DUAL PI3K AND WNT PATHWAY INHIBITION AS A TREATMENT FOR CANCER | INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION | 2016-10-20 | — | — | US | claimed |
| EP-2403832-A1 | N- (HETERO)ARYL, 2- (HETERO)ARYL-SUBSTITUTED ACETAMIDES FOR USE AS WNT SIGNALING MODULATORS | IRM LLC (BM) | 2012-01-11 | — | — | EP | claimed |
| WO-2010101849-A1 | N- (HETERO)ARYL, 2- (HETERO)ARYL-SUBSTITUTED ACETAMIDES FOR USE AS WNT SIGNALING MODULATORS | IRM LLC (BM) | 2010-09-10 | — | — | WO | claimed |
| EP-3964565-B1 | AN IN VITRO METHOD OF DIFFERENTIATING A HUMAN PLURIPOTENT STEM CELL POPULATION INTO A CARDIOMYOCYTE CELL POPULATION | NCARDIA B V (NL) | 2026-04-08 | — | — | EP | disclosed |
| US-20260055367-A1 | METHODS OF MAKING, EXPANDING AND PURIFYING MIDBRAIN DOPAMINERGIC PROGENITOR CELLS | BRAINXELL INC (US) | 2026-02-26 | — | — | US | disclosed |
| US-20250270507-A1 | METHODS FOR PRODUCING CARTILAGE AND BONES | MURDOCH CHILDREN'S RESEARCH INSTITUTE OF THE ROYAL CHILDREN'S HOSPITAL (AU) | 2025-08-28 | — | — | US | disclosed |
| US-20250241964-A1 | SCALABLE METHOD FOR PRODUCING RETINAL PIGMENT EPITHELIUM (RPE) CELLS | EYESTEM RESEARCH PRIVATE LIMITED (IN) | 2025-07-31 | — | — | US | disclosed |
| EP-4558613-A1 | ENGINEERED HUMAN CARDIAC TISSUE | Murdoch Children's Research Institute (AU) | 2025-05-28 | — | — | EP | disclosed |
| US-20110237573-A1 | N- (HETERO)ARYL, 2- (HETERO)ARYL-SUBSTITUTED ACETAMIDES FOR USE AS WNT SIGNALING MODULATORS | IRM LLC (BM) | 2011-09-29 | — | — | US | disclosed |
| US-20110237573-A1 | N- (HETERO)ARYL, 2- (HETERO)ARYL-SUBSTITUTED ACETAMIDES FOR USE AS WNT SIGNALING MODULATORS | IRM LLC (BM) | 2011-09-29 | — | — | US | disclosed |
| US-20110237573-A1 | N- (HETERO)ARYL, 2- (HETERO)ARYL-SUBSTITUTED ACETAMIDES FOR USE AS WNT SIGNALING MODULATORS | IRM LLC (BM) | 2011-09-29 | — | — | US | disclosed |
| WO-2010101849-A1 | N- (HETERO)ARYL, 2- (HETERO)ARYL-SUBSTITUTED ACETAMIDES FOR USE AS WNT SIGNALING MODULATORS | IRM LLC (BM) | 2010-09-10 | — | — | WO | disclosed |
| WO-2010101849-A1 | N- (HETERO)ARYL, 2- (HETERO)ARYL-SUBSTITUTED ACETAMIDES FOR USE AS WNT SIGNALING MODULATORS | IRM LLC (BM) | 2010-09-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260055367-A1 | METHODS OF MAKING, EXPANDING AND PURIFYING MIDBRAIN DOPAMINERGIC PROGENITOR CELLS | DBH, DACH1, GSK3B | PORCN 4785/4885WNT3A 9/4885PSEN1 1936/4885 |
| US-20110237573-A1 | N- (HETERO)ARYL, 2- (HETERO)ARYL-SUBSTITUTED ACETAMIDES FOR USE AS WNT SIGNALING MODULATORS | WNT1, CTNNB1, WNT3A | PORCN 2999/4885WNT3A 3/4885PSEN1 4417/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.